Effects of exogenous melatonin on sleep and circadian rhythms in women with premenstrual dysphoric disorder. Issue 12 (8th July 2021)

• Record Type: Journal Article
• Authors: Moderie, Christophe; Boudreau, Philippe; Shechter, Ari; Lespérance, Paul; Boivin, Diane B
• Is Part Of: Sleep. Volume 44:Issue 12(2021)
• Publication Date: 2021-07-08
• Subjects: premenstrual dysphoric disorder -- menstrual cycle -- melatonin -- sleep -- circadian rhythm -- mood -- body temperature; Sleep -- Physiological aspects -- Periodicals; Sleep disorders -- Periodicals; Sommeil -- Aspect physiologique -- Périodiques; Sommeil, Troubles du -- Périodiques; Sleep disorders; Sleep -- Physiological aspects; Sleep -- physiological aspects; Sleep Wake Disorders; Psychophysiology; Electronic journals; Periodicals; 616.8498
• DOI: 10.1093/sleep/zsab171
• Languages: English
• ISSNs: 0161-8105

Abstract

Abstract: We previously found normal polysomnographic (PSG) sleep efficiency, increased slow-wave sleep (SWS), and a blunted melatonin secretion in women with premenstrual dysphoric disorder (PMDD) compared to controls. Here, we investigated the effects of exogenous melatonin in five patients previously studied. They took 2 mg of slow-release melatonin 1 h before bedtime during their luteal phase (LP) for three menstrual cycles. At baseline, patients spent every third night throughout one menstrual cycle sleeping in the laboratory. Measures included morning urinary 6-sulfatoxymelatonin (aMt6), PSG sleep, nocturnal core body temperature (CBT), visual analog scale for mood (VAS-Mood), Prospective Record of the Impact and Severity of Menstrual Symptoms (PRISM), and ovarian plasma hormones. Participants also underwent two 24-hour intensive physiological monitoring (during the follicular phase and LP) in time-isolation/constant conditions to determine 24-hour plasma melatonin and CBT rhythms. The same measures were repeated during their third menstrual cycle of melatonin administration. In the intervention condition compared to baseline, we found increased urinary aMt6 ( p < 0.001), reduced objective sleep onset latency ( p = 0.01), reduced SWS ( p < 0.001), and increased Stage 2 sleep ( p < 0.001). Increased urinary aMt6 was correlated with reduced SWS ( r = −0.51, p < 0.001). Circadian parameters derived from 24-hour plasma melatonin and CBT did not differ between conditions, except for an increased melatonin mesor in the intervention condition ( p = 0.01). Ovarian hormones were comparable between the conditions ( p ≥ 0.28). Symptoms improved in the intervention condition, as measured by the VAS-Mood ( p = 0.02) and the PRISM ( p < 0.001). These findings support a role for disturbed melatonergic system in PMDD that can be partially corrected by exogenous melatonin.